A Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe in Asia in High Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately Controlled With Their Statin Therapy
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 04 Apr 2018
At a glance
- Drugs Alirocumab (Primary) ; Ezetimibe
- Indications Hypercholesterolaemia
- Focus Therapeutic Use
- Acronyms ODYSSEY EAST
- Sponsors Sanofi
- 27 Mar 2018 Status changed from recruiting to active, no longer recruiting.
- 14 Feb 2018 Planned End Date changed from 1 Jun 2018 to 10 Aug 2018.
- 14 Feb 2018 Planned primary completion date changed from 1 Jun 2018 to 10 Aug 2018.